Eribulin plus immunotherapy for advanced HER2-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs—eribulin (a chemotherapy) and sintilimab (an immunotherapy that helps your immune system attack cancer)—as a first treatment for women with advanced HER2-negative breast cancer that cannot be removed by surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman aged 18 or older.
- You must have advanced (unresectable or metastatic) HER2-negative breast cancer.
- You should be physically active enough to do light housework or office work (ECOG score 0 or 1).
- If your cancer is hormone-receptor positive, you should have already tried or be eligible for first-line hormone therapy (like tamoxifen or a CDK4/6 inhibitor).
- You cannot have had prior chemotherapy or immunotherapy for metastatic breast cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called ESG401 for people with a common type of breast cancer (HR+/HER2-) that has spread and hasn't responded to at least one chemotherapy. The goal is to see if it works better than standard chemotherapy options.
This trial tests a combination of high-intensity focused ultrasound (HIFU, a non-invasive treatment that uses sound waves to heat and destroy tumor tissue) with the immunotherapy drug toripalimab and standard chemotherapy before surgery for women with a specific type of breast cancer (ER-positive, HER2-negative). The goal is to see if this approach can improve treatment outcomes for women with high-risk disease.
This trial is testing a new medicine as the first treatment for HER2-positive breast cancer that has spread or cannot be removed. It's for women who have not had chemotherapy for advanced disease.
This trial tests a combination of two cancer drugs (eribulin and anlotinib) for women whose breast cancer has spread and stopped responding to previous treatments, particularly antibody-drug conjugates. The study aims to see if this combination can help slow or shrink the cancer.
This trial tests a chemotherapy drug called eribulin, alone or with other medicines, in people with advanced HER2-negative breast cancer that has already been treated with an antibody-drug conjugate (ADC). It aims to see if eribulin can help when standard ADC treatment has stopped working.
This trial tests whether adding trastuzumab to eribulin improves outcomes for people with HER2-positive breast cancer that has come back or spread. It’s meant for patients whose cancer has progressed after prior HER2 and chemotherapy treatments.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.